The EMA (European Medicines Agency) data quality framework provides a set of guidelines and principles for ensuring high-quality data in real-world evidence (RWE) studies in the context of EU medicines regulation. The framework aims to promote the use of RWE in the assessment of medicines, and to ensure that RWE studies are conducted in a rigorous and reliable manner.
The impact of the EMA data quality framework on RWE can be significant. By promoting high-quality data collection and analysis in RWE studies, the framework can help to ensure that the results of such studies are reliable and can be used to inform regulatory decision-making. This, in turn, can facilitate the timely access of patients to new treatments and can help to improve public health outcomes.
The framework encourages the use of transparent and reproducible methods in RWE studies, which can help to ensure that the results are credible and trustworthy. The use of standardized data collection and analysis methods can also facilitate the comparison of results across different studies and settings, which can help to build a more comprehensive understanding of the safety and efficacy of medicines.
Overall, the EMA data quality framework can help to promote the use of RWE in medicines regulation and improve the quality and reliability of RWE studies. This can have a positive impact on public health by facilitating timely access to new treatments and improving the understanding of the safety and efficacy of medicines.
Share this story...
Real World Evidence (RWE) 101 – ICH GCP (R3) – Real World Evidence Context
RWE 101 - ICH GCP (R3) - Real World Evidence Context Revision 2 of ICH GCP caused confusion to those of us who work with non-interventional studies. The glossary [...]
Real World Evidence (RWE) 101 – Non-Interventional Studies vs Market Health Research
RWE 101 - Non-Interventional Studies vs Market Health Research Key differences between a non-interventional study (NIS) and market health research include:1. Research Objective: NIS are conducted to examine real-world [...]
Real World Evidence (RWE) 101 – Real World Evidence (RWE) 101 – Audits vs Inspections
RWE 101 - Real World Evidence (RWE) 101 - Audits vs Inspections In the context of regulatory compliance for Real-World Evidence (RWE), both audits and inspections play crucial roles, [...]
Real World Evidence (RWE) 101 – A Career of Many Pathways
RWE 101 - A Career of Many Pathways Real-world evidence (RWE) refers to the information on health care that is derived from analysis of real-world data (RWD). RWE [...]
Real World Evidence (RWE) 101 – Evolution of Regulatory Affairs
RWE 101 - Evolution of Regulatory Affairs Real-world evidence (RWE) and real-world data (RWD) are increasingly influencing regulatory affairs in the biopharmaceutical and healthcare industry. This change has been [...]
Real World Evidence (RWE) 101 – Project Managers
RWE 101 - Project Managers Real-World Evidence (RWE) observational studies and clinical trials are both key elements of medical research, but they involve very different methodologies, aims, and requirements. [...]